The new weight-loss option will cut what the plan sponsors pay as well as what the patients pay, Cigna’s PBM Evernorth says.

Adults with obesity using a GLP-1 have a similar risk for obesity-related cancers as those who undergo bariatric surgery, ...

Unless you are from another planet, you’ve heard all about the new weight loss medications taking the world by storm. These ...

Researchers have discovered that tirzepatide and semaglutide impact energy metabolism in distinct ways. New animal research ...

While some Ozempic faces are appearing older with sunken cheeks, gaunt eyes and sagging neck skin — that doesn’t seem to be ...

Novo Nordisk will sell a less expensive one-month supply of Wegovy for patients who previously took compounded versions of the medication.

India's healthtech space is expected to witness disruption as weight loss drugs Ozempic and Mounjaro enter the market through ...

Novo Nordisk boosts Wegovy access with discounts as FDA bans compounded semaglutide drugs and cracks down on weight-loss copycats.

After four years, those who took GLP-1 drugs had a 7% lower risk of developing an obesity-related cancer and an 8% lower risk ...

Researchers found GLP-1s may modestly reduce the risk of 14 obesity-related cancers, especially colorectal cancer, when compared to a weight-neutral medication used to treat diabetes.

Dr. Rubinstein has years of experience working with patients to help them achieve their desired goals in a realistic, ...

Widely used GLP-1 drugs for type 2 diabetes such as Novo Nordisk's Ozempic may modestly reduce the risk of obesity-related ...